Zoulim du 2012

Hépatite B

Fabien ZoulimDépartement d’hépatologie

& INSERM U871, Lyon

Natural history of hepatitis BAcute infection

Chronic infection: 400 million carriers !

Immune tolerance

Chronic hepatitisInactive carrier

Resolved infection5% neonates90% adults

Wild type virus HBeAg+ Pre-core mutant HBeAg-

Cirrhosis

Hepatocellular carcinoma

Reactivation

30-50 yearsSeeger, Zoulim, Mason; Fields Virology; 2007

EPIDEMIOLOGIE DE L’HÉPATITE B

EPIDEMIOLOGIE DE L'INFECTION A VHB

• Hépatites aigues – VHA : 40%

– VHB : 30%– VHC : 20%

• incidence : 300 000 infections à VHB / an

• 30 000 nouveaux porteurs chroniques / an• 3 000 décès / an

AUX USA

MODES DE TRANSMISSION DU VIRUS DE L'HÉPATITE B EN EUROPE

sexuelle34%

hétéro23%

homo11%

drogue IV26%

inconnue31%

hémodialysés8%

transfusions2%

personnels de santé 2%

contact avecporteur du VHB

AsieTransmission verticale

Déclaration obligatoire de l’hépatite B en France :

résultats des 12 premiers mois de notification

Denise Antona, E Delarocque-Astagneau, D Lévy-Bruhldépartement des maladies infectieuses

Results

158 acute hepatitis cases

• Hospital doctor in 64% cases

• Sex ratio M/F : 2,95 (118/40)

• Median age: 37 yrs for males, 36yrs for females

• Jaundice : 69%

• Hospitalisation : 46%

• Fulminant hepatitis : 3 (2 death)

Risk exposure within 6 months preceding the acute case

Source : obligatory declaration 2003-04

• Source: obligatory declaration march 03- february 2004 N=145

– Sexual 59 40,6% No factor 43 29,6%– IVDU 9 6,2% >1 factor 38 26,3%– Invasive treatment 15 10,3% – Tatoo, piercing 5 3,4% – Familial 14 9,7%– Perinatal 2 1,4%– Live in instiution 11 7,6%– Travel in endemic 21 14,5% areas91/145 patients (63 %) had a vaccine indication (2 vaccinated ≥ 3 doses)

• Sentinel networks 91-96 N=195

–sexual 35% –IVDU 19%–« percutaneous » 15%–No factor 35%

Surveillance épidémiologique de l’infection HBV

• 14 446 adultes testés• Prévalence de l’AgHBs 0,65% (280 000 porteurs

chroniques du VHB)• Homme 1,1% versus 0,2% femme• Naissance en zone d’endémie 4% versus 0,5%• Précarité, séjour en institution, homosexualité,

usage de droguesMeffre et al, J. Med Virol 2004

Hépatites virales B: épidémiologie

- Vaccin mais 400 millions de porteurs chroniques dans le monde- 280 000 porteurs chroniques en France (INVS)- 45% ignorent leur statut- 1 300 décès par an en France- 60 000 avec hépatite chronique active- Environ 15 000 patients traités

VIROLOGIE

• FAMILLE : Hepadnaviridae, seul représentant humain

•VIRUS RESISTANT : - 7 jours dans l’environnement - pendant 5 mn à 100°C, 10 h à 60°C - à la congélation.

LE VIRUS DE L ’HEPATITE B

S small surface protein

M middle surface protein

L large surface protein

core capsid protein

HBeAg secreted e antigen

pol polymerase

HBx X protein (non-secreted)

spherefilament

Dane particle

The HBV genome

Tiollais, Nature 1985

déterminant avaccin/IgHBs

Gène pol antiviraux

Mt pre-coreRéponse anti-HBe ?

Mt du coreRéponse CTL

8 génotypesA to H

The viral replication cycle

Zoulim & Locarnini, Gastroenterology 2009

Transgenic miceHumanized mice

HumanChimpanzeeGibbonbaboons

Tupaïa

Woolley monkey

Ground squirrel

American woodchuck

Pekin DuckGrey Heron

Summers PNAS 1978, Mason J Virol 1981, Chisari Science 1985, Petersen PNAS 1998, Lanford PNAS 1998

The animal models of HBV infection

• Polymerase virale– DHBV : lysat réticulocytaire

– HBV : baculovirus

Modèles in vitro

UPolymerase VHB

DNA(-)

ELONGATIONCCC -

RC -L -

• Culture cellulaire

– Transfection : lignées d’hépatome

– Infection : hépatocytes primaires, HepaRG

– Baculovirus ou adenovirus recombinant

Sells PNAS 1987, Wang Cell 1992, Zoulim J Virol 1994, Lanford J Virol 1995, Gripon PNAS 2002, Sprinzl J Virol 2001

Comparative dynamics among three viruses

(Tsiang et al. Hepatology 1999)

Infection à VHB et risque de CHC

• Etude de Beasley à Taiwan – risque relatif = 100 chez les porteurs de l'AgHBs

• Etude de Tsukuma– risque cumumatif de CHC à 3 ans

• 12,5% chez 240 patients avec cirrhose• 3,8% chez 677 patients avec hépatite chronique

– risque x 7 si AgHBs +– risque X 4 si anti-HCV +

• Facteurs associés : alcool, tabac, aflatoxine• Diminution incidence avec la vaccination de masse (Chen,

NEJM 1995)

CARCINOME HEPATOCELLULAIRE ET VIRUS DE L'HEPATITE B

• Co-incidence de répartition géographique VHB / CHC

• Porteurs AgHBs : RR x 100 pour le CHC• CHC dans les modèles animaux de l'hépatite B :

– marmotte– écureuil

• Présence d'ADN viral intégré dans les tumeurs

HBV replication and its role in HCC development

Wands, NEJM 2004

Role du VHB dans l’oncogénèse hépatique

VHBINFECTION CHRONIQUE

CARCINOGENESCO-FACTEURS

REACTION INFLAMMATOIRE CHRONIQUEREGENERATION HEPATIQUE

MUTAGENESE INSERTIONNELETRANSACTIVATION DE GENES CELLULAIRES

INTERACTIONS PROTEIQUESINACTIVATION DE GENES SUPPRESSEURS DE TUMEUR

PHYSIOPATHOLOGIE / IMMUNOPATHOLOGIE

Ganem and Prince, NEJM 2004

HÉPATOCYTE INFECTÉ

Fasperforine

HÉPATOCYTENON INFECTÉ

IMMUNOPATHOGÉNIE DES HÉPATITES B CHRONIQUES

AgHBc/e

cytokines

RÉPONSE IMMUNITAIRECYTOKINES

ANTIVIRAUX

ANTICORPS NEUTRALISANTS

IMMUNOPATHOLOGY OF HBV INFECTION

Immune tolerance

Clearance phaseChronic hepatitis

SeroconversionRemission

CD8+ HBV

Immunopathology

Fulminant hepatitis

Non cytolytic processesTH1 cytokines with direct antiviral

effect

Turn-over of infected cellsImmune mediated lysis of infected cells

DucksWoodchucks

(Guo J Virol 1999Summers PNAS 2003&2004)

Transgenic miceChimpanzees

(Guidotti Science 1999, Thimme J Virol 2003)

AntiviralsInhibition of viral DNA synthesis-> inhibition of intracellular recycling of cccDNA(Werle Gastroenterology 2004)Restoration of anti-HBV immune response(Boni Hepatology 2000)

MECHANISMS OF VIRAL CLEARANCE

Non cytolytic clearance of acute

Wieland S et al, PNAS 2004

Hepatocyte turn-over is required for clearance of

Summers et al, PNAS 2003 & 2004

Hépatocyte infecté

Hépatocyte non infecté

Phase de tolérance immunitaire

MarqueursAgHBe +HBV DNA +++ALAT = NFoie = N

HBc/e Ag

Fasperforine

Phase de clairance immune(hépatite chronique)

MarqueursAgHBe+HBV DNA > 2000 IU/mLALAT +++Foie: Hépatite chronique

HBc/e Ag

cytokines

HBs Ag

MarqueursAgHBe-anti-HBe +HBV DNA < 2000 IU/mLALAT = NFoie = rémission

Phase de rémissionportage inactif de l’AgHBs

RéactivationVirus sauvage ou mt pre-coreOncogénèse

CD8CD4

Hépatocytes infectés

Hépatocytes non infectés

MarqueursHBsAg -

anti-HBc +Anti-HBs +/-

PCR sérum (-) / foie (+)

Clairance de l’AgHBs

Mutants d’échappementInfections occultesOncogénèse

CD8CD4

cccDNA levels in the different phases of chronic HBV infection

• HBeAg+ patients had significantly higher cccDNA (90-fold) and total HBV DNA (147- fold) levels compared to HBeAg- patients. (p<0.001, Wilcoxon tests)

HBeAg+ (63)

Inact. Carrie

rs (10)

HBSAg- (7)

HBeAg- (18)

HBeAg+ (63)

Inact. Carrie

rs (10)

HBSAg- (7)

HBeAg- (18)

Werle et al, Gastroenterology 2004

Inactive HBV carrier● Not virologically inactive:

– low levels of viremia– episomal HBV DNA in the liver

LOW-REPLICATIVE STATE HIGH-REPLICATIVE STATE– spontaneously– during immunosuppression

Low-replicative or latent infectionEpigenetic control

Histones

CBPPCAFp300

CBPPCAF

p300Sirt1

Sirt1HDAC1HDAC1

Histones

Pollicino et al., Gastroenterology 2006

Pollicino et al. Gastroenteroplogy 2006Levrero et al. J Hepatol, 2009

HISTOIRE NATURELLE ET VIROLOGIE CLINIQUE

Histoire Naturelle de l’hépatite BInfection aigue

Infection chronique

Tolérance immunitaire

Hépatite chroniquePortage inactif

Guérison5% nx-nés90% adultes

Virus sauvage (HBeAg+) Mutant pre-core (HBeAg-)

Cirrhose

Carcinome hépatocellulaire

Réactivation

30-50 ans

Seeger, Zoulim, Mason; Fields Virology; 2007

Seeger, Zoulim, Mason – Fields Virology 2007

HEPATITE B AIGUE• Incubation 1 à 6 mois• Le plus souvent asymptomatique

– Évolution plus fréquente vers la chronicité• Prodromes:

– Maladie sérique : arthralgies, urticaire, acrodermatite etc. ..

• Formes ictériques : + graves que VHA et VHC– Durée de l’ictère : jusqu’à 4 mois

• Evolution : chronicité 5 à 10%• Hépatites fulminantes

Laboratory Diagnosis of Acute Hepatitis B

0 1 2 3 4 5 6 12 24 36 48 60

HBV DNA

Normal

Months After Exposure

Symptoms

Anti-HBs AbAnti-HBe Ab

IgM anti-HBc

Total anti-HBc

Seeger, Zoulim, Mason, Fields Virology 2007

HEPATITE B PROLONGEE

• Définition– Persistance réplication virale à la 8ème

semaine d’évolution :– AgHBe + ou ADN-VHB +

• Evolution– Chronicité : 8 cas / 10

• Traitement : IFN – Guérison : 7 à 8 cas / 10

INFECTIONS CHRONIQUES A VHBFORMES CLINIQUES

• virus sauvage– tolérance immunitaire– rupture de tolérance -> lésions hépatocytaires : HCA– séroconversion anti-HBe spontanée (portage inactif) :

5-10% /an– > diminution significative réplication virale– > amélioration signes histologiques

• virus muté pré-C (-)– sélection au moment de la séroconversion anti-HBe– dépend du génotype viral– immunopathologie ?– sévérité de l'hépatopathie : controversée– association au CHC

0 1 2 3 4 5 6 12 24 36 48 60

HBV DNA

Normal

Laboratory Diagnosis of Chronic Hepatitis B associated with wild type virus infection

`` HBsAg

HBV DNA

Normal

Anti-HBe

Laboratory Diagnosis of Transition of Chronic Hepatitis B to The inactive Carrier State

0 1 2 3 4 5 6 12 24 36 48 60 72 80 92 104

0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48

HBV DNA

Normal ALT levels

Months

l Anti-HBeHBeAg

Laboratory Diagnosis of HBeAg negative Chronic Hepatitis B

1000 ALAT

ADN-VHB

AgHBe + anti-HBe +UI/mlpg/ml

Tolérance hép chronique p. inactif mt pré-core VHB occulte

hybridation

Dynamic ranges of quantificationof HBV DNA assays

Amplicor HBV Monitor v2.0 (Roche)

HBV Hybrid-Capture II (Digene)

Ultra-sensitive HBVHybrid-Capture II

Versant HBV DNA3.0 (bDNA, Siemens)

Cobas Taqman HBV(Roche)

Abbot Real-time HBV(Abbott)

Versant HBV DNA 1.0(kPCR, Siemens)*

*in development

10 102 103 104 105 106 107 108 109

RealArt HBV LC PCR(Artus Biotech)

Formes cliniques

MANIFESTATIONS EXTRAHEPATIQUES DU VHB

• PAN– Complexes immuns circulants HBs/anti-HBs– Dépots artères moyens et petit calibre– Traitement : plasmaphéreses, corticoides, antiviraux

(vidarabine / IFN / famciclovir / lamivudine)• Glomérulonéphrites• Cryoglobulinémies• Guillain-Barré• Myocardite

TRANSMISSION VERTICALE DU VHB

• mère AgHBe + – transmission : 90%

• mère anti-HBe +– transmission : 10-20%– VHB muté pré-C (-) : hépatites fulminantes

• chronicité chez l’enfant : 90%

PRESENTATION CLINIQUE• INFECTION PERI-NATALE

– ALT normales ou subnormales– ADN-VHB > 1000 pg/ml

– histologie : lésions minimes• INFECTION POST-NATALE

– ALT élevées– ADN-VHB < 1000 pg/ml

– histologie : hépatite modérée à sévère

Pathophysiologic Cascade of

HBV Replication(Measured by

Serum HBV DNA)

Liver Inflammation

Worsening Histology• Necroinflammation• Fibrosis• Cirrhosis

Disease Progression• Liver Failure• Liver Cancer• Transplant• Death

Adapted from: Lavanchy D. Journal of Viral Hepatitis, 2004, 11, 97–107. Chen JC, et al. JAMA. 2006;295:65-73. Iloeje U. H, et al. Gastroenterology. 2006;130:678-86.

ALT Elevation

Charge virale et incidence de la cirrhose

R.E.V.E.A.L. – HBV Study

Année de suivi

0 1 2 3 4 5 6 7 8 9 10 11 12 13

P <0.001

n=37741.0 x 106 n=6271.0-9.9x105 n=3441.0-9.9x104 n=649300-9.9x103 n=1210<300 n=944

5.2%6.3%

Iloeje UH et al. Gastroenterology 2006; 130: 678-686

Survie chez les patients au stade cirrhose

1. Weissberg et al. Ann Intern Med. 1984;101:613. 2. De Jongh et al. Gastroenterology. 1992;103:1630.

1 32 4 50

Cirrhosis1

(n = 130)

Decompensated cirrhosis2

(n = 21)14%

Charge virale et incidence du CHC

Chen et al; JAMA 2006

REVEAL-Incidence of HCC

Chen JC, et al. JAMA. 2006;295:65-73.

3.6%1.4%1.3%

<300 >300 - 103

Baseline HBV DNA (copies/mL)

> 103 - 104 >104 - 106 ≥106

High Baseline Serum HBV DNA Levels are Associated with Increased Risk of HCC Mortality

in HBsAg-Positive Patients

80 %82 %84 %86 %88 %90 %92 %94 %96 %98 %

0 1,0 2,0 3,0 4,0 5,0 6,0 7,0 8,0 9,0 10,0 11,0 12,0

Survival time (Years)

HBV DNA Negative

HBV DNA Low< 105 copies/mL RR = 1.7 (0.5-5.7)

HBV DNA High≥ 105 copies/mL

RR = 11.2 (3.6-35.0)p < 0.001 across viral categories

http://www.fccc.edu/docs/sci_report/Evans.pdf#search=%22haimen. Accessed 1/23/07.Chen G, et al. J Hepatology 2005; 42 (suppl 2):477A.Chen G, et al. Hepatology 2005; 40 (suppl 1):594A.

Relationship Between Persistent Viremia and HCC: Argument For Antiviral Therapy

• Persistent replication associated with greater risk of HCC• Decreased risk when viral replication declines

Chen, et al. JAMA 2006

Baseline HBV DNA, (copies/mL)

< 104 ≥105 ≥105 ≥105

Follow-up HBVDNA, copies/mL --- < 104 104 to <105 ≥105

Adjusted RR (95% CI)

1.0(ref)

3.6(1.7-7.6)

6.9(3.4-13.8)

9.1(5.8-14.1)

P Value -- < 0.001 < 0.001 < .001

873010,108

2.0x103

4.0x1036.0x1038.0x1031.0x104

1.2x104

Impact Clinique de la Variabilité du

VARIABILITE GENETIQUE DU VHB

• Multiplication virale» taux d'erreur de la transcriptase inverse

• Pression de sélection» réponse immunitaire cellulaire / humorale» antiviraux-> possibilité de variants d'échappement

• Conséquences cliniques» diagnostic sérologique» traitements antiviraux

8 genotypes, numerous sub-genotypes, and recombinant forms

World J Gastroenterol 2007; 13: 14-21

Génotypes VHB chez les patients atteints d’hépatite chronique en France

F GA B C D E0

0.4 % 1.1%

Zoulim et al J Viral Hepatitis 2006

Impact du génotype sur la séroconversion Hbe/HBs

1 Janssen, Lancet 2005; 2 Flink, Am J Gastro 2006

PEG-IFN a-2b

HBeAg Loss 1

A n=90

47%44%

C n=39

D n=103

HBV genotype

A n=90

C n=39

D n=103

HBV genotype

PEG-IFN a-2b

HBsAg Loss 2

LES MUTANTS DU GÉNOME DU VHB

déterminant avaccin/HBIg

polyméraseantiviraux

Mt pré-coreRéponse anti-e ?

Mt coreRéponse CTL

ROLE DE LA RÉGION PRÉ-C ET DE L’AgHBe

• Non nécessaire à la réplication du VHB– Culture cellulaire– Modèles in vivo

• Marmotte• Canard

• Modulation de la réponse immune– Tolérogène : souris transgéniques– Cible de la réponse anti-capside

Chang et al, J. Virol 1987; Schlicht et al J. Virol 1987; Chen J. Virol 1992; Millich et al PNAS

LES MUTANTS PRÉ-C (-)• codon stop / région pré-C

TGG -> TAG en pos. 1896

– génotypes B à E (A : exceptionnel)

– arrêt traduction protéine pré-C/C

– AgHBe négatif

• mutation dans promoteur pré-C

TTAAAGG -> TTAATGA en pos. 1762 /1764

– génotypes A à E

– transcrits pré-C/C :

– synthèse d'AgHBe :

Carman et al Lancet 1989, Okamoto et al J Virol 1990/1994, Tong et al Virology 1990

HBeAg and Precore Mutation

1814 1901

Precore Coreregion region

G 1896A = stop codon, TAG

ATG ATG

Virion

Core gene

HBeAg and Precore Mutation

1814 1901

Precore Coreregion region

ATG ATG

Virion

Core gene

VARIANTS NÉGATIFS POUR L ’AgHBe

Protéinepré-C/C

PRE-C CPROMOTEUR

TAG***

1762-1764 1896

arrêt des synthèses protéiques

Diminution de l’expression de l ’AgHBe

Sélection des mutants pré-core au cours de l’histoire naturelle de l’hépatite B chronique

ADN-VHB

AgHBe Anti-HBe

sauvage

Mt pré-C

Outcome of Chronic Anti-HBe Positive Hepatitis B

1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566

1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465

Biochemical patterns in 164 untreated patientsafter 23 months (range 12-36) monthly monitoring

0 12 24 months

With flares and normalization

Without flares

With flares and without normalization

73 pts ( 44.5% )

59 pts ( 36.0% )

32 pts ( 19.5% )

Asymptomatic flare-up:

90% of cases

ALT Flare-up yearly

frequency:once 57.1%twice 20%

< once 22.8%

Brunetto MR et al, J Hepatol 2002

Augmentation de prévalence des hépatites chroniques avec AgHBe négatif en France

HBeAg(+)HBeAg(-)

42%N=119

58 %N=164

Zoulim et al, J Viral Hepatitis 2006

No pre-core mutation (n = 42; 14.8%)

Both mutations (n = 95; 33.6%)

Promoter mutation (n = 99; 27.9%)

Stop codon mutation (n = 55; 19.4%)

Data unavailable (n = 12; 4.2%)

Pre-core mutations

Lamivir cohort, Zoulim et al, J Viral Hepatitis 2006

MUTANTS PRÉ-C ET SÉVÉRITÉ HISTOLOGIQUELA CONTROVERSE

• Italie– Cirrhose plus fréquente

• Bonino Gastroenterology 1986, Fattovich Hepatology 1988

• France– Activité idem / cirrhose plus fréquente

• Zarski et al, J Hepatol 1993• Grandjacques et al, J Hepatol 2000• Zoulim et al, J Viral Hepatitis 2006

• Asie– Mt promoteur : activité histologique et fibrose plus importante– Mt pré-C : activité histologique moins importante

• Lindh et al, J Infect Dis 1999– Rémission histologique

• Chan et al, Hepatology 1999• Afrique

– Mt promoteur : plus fréquents dans le CHC• Baptista et al, Hepatology 1999

HBe serotype and liver pathology

0-4 5-9 10-14 15-220

Knodell score

Metavir score

≤ F2 F3 F40

HBe-positive

HBe-negative

Lamivir cohort, Zoulim et al, J Viral Hepatitis 2006

HÉPATITES FULMINANTES ET MUTANTS PRE-C• Lien de causalité :

– Épidémies hépatites fulminantes

– Transmission souche mutée pré-C (-)

– Rôle immunomodulateur de l ’AgHBe

• Pas de lien de causalité

– Séquençage génome complet

– Pas de profil commun de mutation

Stuyver et al, Hepatology 1999, Sternbeck et al Hepatology 1996, Liang et al, NEJM 1991

DIAGNOSTICS DIFFICILES

Diagnosis of inactive carrier versus HBeAg negative chronic hepatitis

• Inactive Carrier– Persistently normal ALT levels– Persistently low levels of serum HBV DNA

• Threshold : 2,000 IU/ mL (see EASL CPG J Hepatol 2009)

• HBeAg negative chronic hepatitis– Fluctuation / exacerbation of ALT– Fluctuations of HBV DNA levels usually > 2000 IU/ mL– Presence of pre-core / core promoter mutations

DIAGNOSTIC D'UNE EXACERBATION AIGUE SUR HEPATITE B CHRONIQUE

• Définition : poussée cytolytique≠ réactivation virale

• Ag HBe + initialement– rupture de tolérance immunitaire– séroconversion anti-HBe– très fréquent chez patients asiatiques

• Anti-HBe + initialement– réactivation virus sauvage : -> AgHBe +– réactivation virus muté pré-C (-)– Corticothérapie, biothérapie, chimiothérapie– surinfection delta / VHC

137149

99 NH2

S - S S - S

139147

Tiollais P. et al., Nature 1985. Torresi J., J. Clin Virol 2002; Dryden KA. et al., Mol Cell 2006

« a » determinant

HBs Ag

« a » determinant induces the synthesis of anti-HBs neutralizing antibodies

sG145R

sP120T

sD144H/A/E

PreS1PreS2

Pré-C

Brin(+) 2,4kbBrin(-) 3,2kb

TATAAU5-like

DR2Enh1Enh2

GRE0/3221

SHBs (S)MHBs (preS2+S)LHBs (preS2+preS2+S)

Variants de l'Ag HBs

• échappement à la réponse humorale anti-HBs

– naturelle

– vaccination (transmission mère-enfant)

– immunoprophylaxie (transplantation hépatique)

• infection active malgré Ac anti-HBs

• sérologie AgHBs faussement négative

Risques : transmission virale + infections occultes

VARIANTS DE L'AgHBs

• Mutations ponctuelles dans le déterminant a de l'AgHBs (124-147)

– aa 145 : Gly -> Arg

– aa 126 : Ile -> Ser / Thr -> Asn

• transmission mère-enfant malgré la serovaccination (3%)

• infection du greffon hépatique malgré Immunoglobulines anti-HBs

• hépatites chroniques avec anti-HBc et anti-HBs +

Presence of HBV DNA in the liver (± serum) of

individuals testing HBsAg negative by currently available assays

Occult HBV Infection (OBI)

Raimondo et al, J Hepatol 2008

How to Detect Occult HBV Infection

Currently there is no standardized

diagnostic assay for occult HBV infection

Reported Prevalence of Occult HBV Infection in HIV Positive Patients

Study Country N° ofpatients

Occult HBVN° (%) Methods

Hofer, 1998 Switzerland 57 51 (89%) “nested” PCR(serial evaluation)

Torres-Baranda, 2006 Mexico 35 7 (20%) “nested” PCR

Filippini, 2006 Italy 86 17 (20%) single step PCR

Mphahlele, 2006 South Africa 140 31 (22.%) “nested” PCR

Pogany, 2005 Netherlands 93 4 (4%) single step PCR

Neau, 2005 France 160 1 (0.6%)

Santos, 2003 Brazil 101 16 (16%) single step PCR

Wagner, 2004 France 30 11 (37%) “nested” PCR

Goncales, 2003 Brazil 159 8 (5%) “nested” PCR

Nunez, 2002 Spain 85 0 Cobas Amplicor HBV Monitor (Roche)

Piroth, 2000 France 37 13 (35%) single step PCR

Raffa, 2007 Italy “nested” PCR (liver)

Cobas Amplicor HBV Monitor (Roche)

101 42 (41%)

Raimondo et al, J Hepaol 2007, modified

Cause(s) for the failure of HBsAg detection

Suppression ofHBV replication and

gene expressionInfection by

S gene Variants

“false” OBI

Occult HBV infection

HBV cccDNA Integrated HBV DNA

HBV mutants Epigenetic control

HBV replication

Immune surveillanceViral co-infections

Seropositive Seronegative

HBsAg lost during CH

HBsAg lost after AH

Progressive antibody disappearence

Primary occult

Schematic representation of HBV serum marker profile in OBI and “false” OBI

„false“ OBI

S gene escape mutants

HBV DNA levels comparable to overt infection

HBV DNA levels < 200 UI/ml

Occult hepatitis BTorbenson M. & Thomas D.L., Lancet Inf Dis, 2002

High prevalence

ROLEin

Diagnostic

Tools ?

Worsen HCVinfection ?

Co-infections ?Therapy?

To beimproved

Specific treatments ?

Not fully understood ?

Occult HBV infections: unresolved issues

AntivirauxPersistance virale

Resistance aux antivirauxMonitoring des traitements

HBeAg(+) HBeAg(-) / anti-HBe(+)

HBV DNA

Minimal CH Moderate to severe CH Moderate to severe CHRemission

Cirrhosis

Immunotolerantphase

Immuno-activephase

Inactive phaseLow replication

Reactivation phase

Cirrhosis

109-1012 IU/mL >2000-<109 IU/mL <2000 IU/mL >2000 IU/mL

Inactive cirrhosis

Adapted from Fattovich G. Sem Liver Dis. 2003

Treatment indicated Treatment indicated

HBsAgOccult infection

Antivirals approved for hepatitis B

*Currently approved for HIV**development on hold

Drug Type Approved Phase 3 Phase 2Nucleoside analogs • Lamivudine*

• Entecavir • Telbivudine

• Emtricitabine*• Clevudine**

Nucleotide analogs • Adefovir dipivoxil• Tenofovir*Cytokines • Interferon alfa• Pegylated Interferon alfa-2a

• IL7•IFN Lambda•Vaccine therapy

Endpoints of therapy

Persistence of high viral load is associated with a significant risk of progression of the liver disease and of HCC

Aim of antiviral therapy:

HBV DNA < 10-15 IU/mL by real-time PCR assays

No replication=

No resistance

Viral suppression

Histological and clinical improvement

Chen CJ, et al. JAMA 2006. Iloeje UH, et al. Gastroenterology 2006. Chen C, et al. Am J Gastroenterol 2006. Zoulim & Perrillo J Hepatol 2008. Zoulim & Locarnini Gastroenterology 2009

Treatment failure

Primary non responsePartial response

Secondary treatment failureAntiviral drug resistance

Host factorsDrug metabolismPatient’s compliance

Drug factorsAntiviral potency

Drug factorsBarrier to resistance

Viral factorsResistant mutants

Zoulim et al Hepatol 2008; EASL CPG J Hepatol 2009; Lancet Infect Dis 2012

Clinical definition of resistance

• Virologic Breakthrough: Rebound in serum HBV DNA levels (e.g. 1 log10 above nadir)

• Genotypic Resistance: Detection of mutations known to confer resistance while on therapy

• Virologic Breakthrough with Genotypic Resistance: Viral rebound associated with a mutation(s) known to cause resistance.

• Primary non response: <1log10 decrease of viral load after 3 months

• Partial response: detectable HBV DNA levels during therapy

Zoulim & Perrillo, J Hepatol 2008; EASL CPG, J Hepatol 2009

Laboratory Definition of HBV Resistance to Antivirals

Laboratory Investigations• Phenotypic Resistance: Decreased susceptibility (in vitro

testing) to inhibition by anti-viral drugs associated with genotypic resistance.

• Cross Resistance: Mutants selected by one agent that also confer resistance to other antiviral agents

Zoulim et al; Future Virology 2006

The main differences between HIV, HBV and HCV

HBV1,2

Host cell

cccDNA

Host DNA

Integrated DNA

Nucleus

Host cell

Host DNA

Proviral DNA

Nucleus

HCV1,3

Host cell

Host DNA

Nucleus

HCV RNA

Life-long suppression of viral replication

Definitive viral clearance and SVR

Long-term suppression of viral replication

Adapted from 1. Sorriano V, et al. J Antimicrob Chemother 2008;62:1-4. 2. Locarnini S and Zoulim F. Antiviral Therapy 2010;15 (suppl 3):3-14. 3. Sarrazin C and Zeuzem S. Gastroenterology 2010;138:447-462.

Si Ahmed et al. Hepatology. 2000; Yuen et al Hepatology 2001; Locarnini et al Antiviral Therapy 2004; Villet et al Gastroenterology 2006 J Hepatol 2007 & 2008; Pallier et al J Virol 2007; Yim et al Hepatology 2006.

Kinetics of emergence of HBV drug resistant mutants

Lamivudine Resistance Accelerates Progression of Liver Disease

0 9 18 27 36

Time after randomization (Months)

Placebo (N=215)YMDDm (N=209) (49%)Wild Type (N=221)

Placebo

Liaw YF et al. N Engl J Med. 2004;351:1521-1531

Biochemical and Histologic Correlates of HBV Resistance

• Rise in ALT levels– Mild ALT elevations in most cases– ALT flares with acute exacerbations and liver failure:

especially patients with liver cirrhosis and/or pre-core mutant infection

• Progression of liver disease– Progressive worsening of liver histology– Clinical deterioration, liver decompensation, HCC

developmentLai et al Clin Infect Dis 2003; 36: 687-696; Dienstag et al Gastroenterology 2003;124:105-117 ; Lok et al Gastroenterology 2003; 125 : 1714-1722; Hadziyannis et al Hepatology 2000;32:847-851; Si Ahmed et al Hepatology 2000; Zoulim et al J Viral Hepatitis 2006;13:278-288 ; Fung et al J Hepatol 2005;43:937-943; Liaw et al NEJM 2004;351:1521-1531.

ALT flares in patients with lamivudine resistance over time

Lok et al Gastroenterology 2003; 125 : 1714-1722

Drug and patient population

Resistance at year of therapy expressed as percentage of patients

Drug and patient population 1 2 3 4 5 6

Lamivudine 23 46 55 71 80 -

Telbivudine HBeAg-Pos 4.4 21 - - - -

Telbivudine HBeAg-Neg 2.7 8.6 - - - -

Adefovir HBeAg-Neg 0 3 6 18 29 -

Adefovir (LAM-resistant) Up to 20% - - - - -

Tenofovir 0 0 0 0 0 -

Entecavir (naïve) 0.2 0.5 1.2 1.2 1.2 1.2

Entecavir (LAM resistant) 6 15 36 46 51 57

Incidence of drug resistance over time

CL Lai Clin Infect Dis 2003; CL Lai NEJM 2007; Hadzyiannis Gastroenterology 2006;Marcellin NEJM 2008; CL Lai & Chang NEJM 2006; Zoulim & Locarnini Gastroenterology 2009

LVD ADV LdT ETV TDF0

0.2 0.51.2 0

1 2 3 4 5 1 2 3 4 5 1 2 1 2 3 4 5 1 2 30 0

Option to add emtricitabine at

week 72*

*Patients confirmed to be viraemic at Week 72 or beyond could add emtricitabine to TDF at the discretion of the investigator. Clinical data on the safety and efficacy of emtricitabine and TDF in CHB are pending

Rates of resistance with lamivudine (LVD), adefovir (ADV), telbivudine (LdT), entecavir (ETV) and tenofovir (TDF) among NA-naïve patients

High barrier to resistance

Adapted from Gish, Jia, Locarnini & Zoulim, Lancet Infect Dis 2012

Zoulim & Locarnini, Gastroenterology, 2009

Determinants of viral persistence & resistance

Multiple factors are associated with the barrier of resistance & drug efficacy

• Adherence• Immune status• Prior antiviral exposure• Metabolism• Body mass

Patient

Antiviral Drug

• Antiviral potency• Number of mutations needed to overcome drug suppression

• Level of exposure to drug• Chemical structure Virus

Locarnini S, et al. Antivir Ther. 2004;9:679–93. Locarnini S, et al. Antivir Ther. 2007;12:H15-H23. 3. Ghany M & Liang TJ. Gastroenterology 2007;132:1574-85. Zoulim F, et al. Antiviral Res. 2004;64:1-15. Locarnini S, et al. J Hepatol. 2003;39:S124-S132.; Zoulim & Locarnini Gastroenterology 2009

• Replication fitness and space• Persistence of archived mutations as cccDNA

• Pre-existing mutations

L(-)-SddC, 3TCLamivudineL(-)-SddC

mitochondria

nucleus

L(-)-SddC-TP HBV DNA

Nuclear DNA

Mt DNA

L(-)-SddC-TP

cytoplasm

kinase

L(-)-SddUdeaminase

Bridges; Progress in Liver Disease 1995

Nucleos(t)ide analogs

The HBV life cycle

Zoulim & Locarnini, Gastroenterology 2009

uncoating CCC DNA

removal of protein primerremoval of RNA primercompletion of viral (+) strand DNAligation of DNA strands extremities

supercoiled DNAminichromosome

viral polymerase?DNA repair protein?other cellular enzymes?

Topoisomerase (TDP2) ?Acetyl transferase ?Histones

Formation of the recalcitrant cccDNA: a difficult target for antiviral therapy

Tuttleman et al Cell 1986Le Guerhier et al AAC 2000Delmas et al AAC 2002Kock et al Hepatology 2003Cortes Ledesma et al Nature 2009Boeck et al Plos Pathogen 2010

Antivirals ?

Can we prevent cccDNA formation ? Nucleoside analogs in monotherapy or

Kinetics of Viral Loss During Antiviral Therapy with L-FMAU (clevudine) in the woodchuck model

Zhu et al, J Virol 2001

ADV Associated Serum HBsAg Reductions are Similar in Magnitude to cccDNA Reductions

SerumHBVDNA

TotalIntracellular

DNAcccDNA Serum

§ 48 weeks of ADV resulted in significant reductions in : serum HBV DNA > total intrahepatic HBV DNA > cccDNA § Changes in HBsAg levels correlated with cccDNA changes-> 14 years of therapy to clear completely viral cccDNA

Werle et al, Gastroenterology 2004

• 0.8 log10 (84%) decline in cccDNA, not paralleled by a similar decline in the number of HBcAg+ cells

• Suggests cccDNA depleted primarily by non-cytopathic mechanisms or that cell turn-over occurred but was associated with infection of new cells during therapy

Immunohistochemical Staining of Patient Biopsies at Baseline and After 48 Weeks ADV Therapy

Baseline Week 48

Maynard et al, J Hepatol 2005

Persistence of cccDNA after HBs seroconversion

Clearance of viral infection versus selection of escape mutants

The most important factors to consider:

§ The rate of immune killing of infected hepatocytes

§ The rate of replication and spread of mutant virus in the chronically infected liver (I.e. fitness of the virus: the rate of spread to uninfected hepatocytes)

§ Small changes in these factors may have profound effect on whether treatment response is durable or subject to rapid rebound (Litwin et al J Clin Virol 2005)

§ These factors may be subject to therapeutic intervention

Kinetics of spread and emergence of drug resistant virus during antiviral therapy

Zhou T, et al. Antimicrobial Agents and Chemotherapy 1999; 43: 1947-1954.

antiviral

Free liver space

Mutant fitness

ÒÒÒ

I II III IVINHIBITION OF WILD TYPE VIRUS REPLICATIONS DELAYED EMERGENCE OF

DRUG RESISTANT VIRUS

ni = non-infectedwt = wild type

mt = mutant type

Kinetics of HBV drug resistance emergence

Si Ahmed et al. Hepatology. 2000; Yuen et al Hepatology 2001; Locarnini et al Antiviral Therapy 2004; Villet et al Gastroenterology 2006 J Hepatol 2007 & 2008; Pallier et al J Virol 2007; Yim et al Hepatology 2006.

Treatment begins

Drug-resistant variant

Drug-susceptible virus

Naturally—occurring viral variants

Primary resistance mutations

Secondary resistance mutations/ compensatory resistance mutations

Partial response to adefovir dipivoxil is not due to the selection of DR mutants

• The top 25% patients (quartile 1): > 4.91 log10 reduction in serum HBV DNA at week 48. • In Q2: 3.52 to 4.90 log10 reduction of viral load. • In Q3: 2.22 to 3.51 log10 reduction in viral load. • The bottom 25% of patients (Q4):< 2.22 log10 reduction in HBV DNA levels at week

48.• Phenotypic analysis of viral strains: Q4 as sensitive to ADV as Q1 strains• Documented Drug Compliance (% of days without taking ADV)

• Wilcoxon rank sum test, P=0.01 Durantel et al, Antiviral Therapy, 2008

Virological ResponseQ1 (best response)

(n=38)

Virological ResponseQ2

(n=38)

Virological ResponseQ3

(n=38)

Virological ResponseQ4 (worse response)

(n=38)Median 99% 99% 99% 97% a

range 86-100% 41*-100% 91-100% 70-100%

M204V reduces pocket size

Steric clash between lamivudine and V204

Wild-type M204/L180

LVD-TP

LVDr M204V/L180M

LVD-TP

LVDr M204V/L180M

ETV-TP

Langley DR, et al. J Virol. 2007;81:3992-4001.

Amino acid substitutions result in conformation changes of the polymerase catalytic site

Minimal steric clash between entecavir and V204

Definition of fitness

• A parameter that quantifies the adaptation of an organism or a virus to a given environment

• For a virus, ability to produce infectious progeny relative to a reference viral clone, in a defined environment

Esteban Domingo, In Fields Virology 2007

Cross-resistance data for the main mutants and the commercially available drugs

Pathway Amino acid substitutions in the rt domain

Lamivudine Telbivudine Entecavir Adefovir Tenofovir

Wild type S S S S SL-nucleoside M204I R R I S SL-nucleoside L180M+M204V R R I S S

Alkyl phosphonate

N236T S S S R I

Shared A181T/V I/R I/R S R ID-Cyclopentane

(ETV)L180M+M204V/I ±I169T±V173L

±M250V

R R R S S

D-Cyclopentane (ETV)

L180M+M204V/I±T184G±S202I/G

R R R S S

MDR V173L+L180M+A181V+N36T

R R S R S

Zoulim & Locarnini Gastroenterology 2009

• cccDNA in the liver:– Is propagated during the normal

replication cycle of HBV– Can serve as a template for the production

of new virus

Archiving of viral variantsViral quasispecies

cccDNA variants

Liver Majority populationMinority variants Resistant variants

Blood circulation

Zhou et al, AAC 1999; Zoulim F. Antivir Res. 2004. Zoulim F & Perillo R. J Hepatol. 2008

• cccDNA in the liver:– Is propagated during the normal replication

cycle of HBV– Can serve as a template for the production of

new virus

• It is believed that viral variants with antiviral resistance may be archived in this way

cccDNA variants

Blood circulation

• cccDNA in the liver:– Is propagated during the normal replication

cycle of HBV– Can serve as a template for the production of

new virus

• It is believed that viral variants with antiviral resistance may be archived in this way

cccDNA variants

Blood circulation

Phenotyping of HBV clinical isolates

1. Durantel D, et al., Hepatology, 2004;40:855-64. 2. Yang H, et al., Antiv Ther, 2005;10:625-33.

Lab St

Clone A

Clone C

Clone D

Clone E

Southern blotanalysis

Patient serum

PCR cloning

Whole genomeHBV clones

Transfection

HepG2Huh7

IC50 reference strain

IC50 mutantFold resistance =

Wild-type virus

Increasing antiviral concentration

Cell culture plate

Patient’s virus

lamivudine adefovir

ADV rtN236T +/or rtA181V

Wild-type virus

ADV-resistant virus

LAM-resistant virusLAM rtM204V/I ± rtL180M

ETV-resistant virus

rtT184 or rtS202 or rtM250ETV

rtM204V/I rtL180M+/-

TDF: what can we expect?

rtM204V/I +/- rtL180M

LAMthen ETV

rtT184 or rtS202 or rtM250

LAM + TDF – what do we see?

Maximising the barrier to resistance

Can we detect low frequency mutants prior to or during therapy ?

Use of pyrosequencing to detect low frequency mutants

•May detect mutants representing as low as 0.1% of the viral population

•The clinical significance for treatment choice or adaptation needs to be determined by prospective studies

Important factors involved in selection of MDR mutants

• Use of inadequate sequential monotherapies and inadequate treatment adaptation

• Incomplete viral suppression– > Persistent replication in the presence of antiviral pressure

• Use of drugs sharing cross-resistance characteristics– One mutation may confer resistance to several drugs

– > Persistent replication

• Accumulation of mutations

• Wide replication space (liver transplantation)

Multiple drug resistant mutants with complex pattern of mutations

+ one mutation + one mutation

Drug A Drug B

Risk of selection of MDR mutants by sequential therapy- drugs sharing cross-resistance characteristics- incomplete viral suppression- liver transplantation

The problem of sequential therapy with nucleoside analogues

Zoulim F, et al. J Hepatol. 2008;48:S2-19. Yim et al, Hepatology 2006; Villet et al Gastroenterology 2006 & 2009

0 20 40 60 80 100 120

Treatment (months)

entecavirIFNadefovir

lamivudineGenotype H

lamivudine

Drugs sharing cross-resistance characteristics:Switching strategy emergence of MDR mutant

L180M+S202G+M204V

L180M+M204V

Villet et al, J Hepatol 2007

A single a.a. substitution at position rt181 may be responsible for multidrug resistance

Villet S, et al. J Hepatol. 2008;48:747-55.

wtA181VA181TA181V + N236TA181T + N236TN236T

N236T + N238TM204VM204IL80VL80V + M204I

LVD+TDF LVD+ADV+TDF

Patient #1(67 months)

LVD+ADVADV

Impact of rtA181 and rtN236 mutations on antiviral drug efficacy and cross-resistance

Villet et al, J Hepatol 2008

Warner et al Hepatology 2009Kamili et al Hepatology 2009Villet et al Gastroenterology 2009

Impact on virus infectivity and fitnessImpact on virion release (intracellular

retention) and virologic monitoring of breakthrough

Impact on vaccine prophylaxis efficacy

Potential risk of transmission of HBV DR mutants

Clements et al, Bull WHO 2009

Management algorithmAntiviral treatment

Treatment failure

Viral load asssessment

Add-on therapy based on cross-resistance data

Check compliance Primary non response

Switch to more potent drugZoulim and Perrillo, J Hepatol, 2008; EASL CPG J Hepatol 2009

Viral genome sequence analysis

Wild type virus HBV drug resistant mutant

Check compliance

Management algorithm

Antiviral treatment

Treatment response

Viral load asssessment

Zoulim and Perrillo, J Hepatol, 2008; EASL CPG J Hepatol 2009

Check for HBe/HBs seroconversion on a regular basis (6 monthly)

Virologic Consequences of Persistent Viremia

§ Infection of new hepatocytes" slower kinetics of clearance infected cells and cccDNA

§ Increases the risk of occurrence and subsequent selection of HBV mutations responsible for drug resistance

§ On-treatment prediction of HBV drug resistance

Le Guerhier et al Antimicrob Agents Chemoter 2000;44:111-122; Delmas et al Antimicrob Agents Chemother 2002; 46:425-433; Kock et al Hepatology2003; 38:1410-1418; Richman Hepatology 2000;32:866-867

M0M3M6M9M12M15M18M21M24M27M30M33M36

HBV DNA ALTHBV DNA

Month of therapy

Rescue therapy in patients with clinical breakthrough

Drug A

Drug B

M0M3M6M9M12M15M18M21M24M27M30M33M36HBV DNAALTHBV DNA

Month of therapy

Rescue therapy in patients at the time of virologic breakthrough

Drug A

Drug B

M0M3M6M9M12M15M18M21M24M27M30M33M36HBV DNAALTHBV DNA

Month of therapy

Early add-on therapy to prevent drug resistance

Drug ADrug B

Very Early Add-on Therapy to Keep Viral Load as Low as Possible

M0 M3 M6 M9 M12 M15 M18 M21 M24

Drug ADrug A

+Drug B

Month of therapy

1. Start with a drug having a high genetic barrier for resistance2. Add a drug with a different cross-resistance profile

outgrowth of drug resistant mutant ?

Tenofovir DF 300 mg(TDF)

FTC 200 mg / Tenofovir DF 300 mg(FTC/TDF)

Study 106: TDF Versus FTC/TDF for Treatment of CHB in Patients with Persistent Viral Replication Receiving ADV

Double Blind

End of Study

Week 24*

Blinded TDF or

OL FTC/TDF

Blinded FTC/TDF or

OL FTC/TDF

Final Study Results(AASLD 2010)

Berg T, et al., AASLD 2010; Oral# 136.

Week 48 Week 96

*From Week 24 on, patients with confirmed (within 4 weeks) plasma HBV DNA ≥ 69 IU/mL had the option to add FTC (as fixed dose FTC/TDF) or discontinue from the trial and initiate commercially available therapy

Week 168

Blinded TDF or

OL FTC/TDF

Blinded TDF or

OL FTC/TDF

Blinded FTC/TDF or

OL FTC/TDF

Blinded FTC/TDF or

OL FTC/TDF

* From Week 24 on, patients with confirmed HBV DNA ≥ 400 copies/mL (69 IU/mL) could switch to open label (OL) FTC/TDF or discontinue from the trial and initiate commercially available therapy

Study 106 – Treatment-Experienced Patients

Primary Efficacy Analysis:

Comparison of the Two Treatment Strategies

82% FTC/TDF

82% TDF

ITT: NC=F*

Two patients on study at Week 168 had HBV DNA ≥400 copies/mL

Berg T, et al., AASLD 2010; Oral# 136.

*NC=F, Non-completer counted as failure in this ITT analysis, including patients who switched to open-label FTC/TDF fixed-dose combination

Study 106 – Treatment-Experienced Patients

% of Patients with HBV DNA < 400 copies/mL (69 IU/mL)

Virologic response to TDF according to ADV resistance mutations at baseline - The Australian Experience

Patterson S J et al. Gut 2011;60:247-254

Viral load

BL viral load = 6.85logTreatment: TDFAdherence : 68%

Patient 1046 data:

Evolution of viral genome during Tenofovir therapy in patients who prevously failed ADV

Patient #1046

Viral load

BL viral load = 8.75logTreatment: TDFAdherence : 95.2%

Patient 1051 data:

Evolution of viral genome during Tenofovir therapy in patients who prevously failed ADV

Patient #1051

Impact of persisting low viremia levels on treatment outcome ?

Perspectives / Prevention of drug resistance

• First line therapy– Use of antivirals with high antiviral potency and high barrier to

resistance– Combination therapy with complementary drugs to increase the

barrier to resistance• Second line treatment

– Add-on strategies with complementary drugs preferred to sequential monotherapies

– Early treatment adaptation to prevent accumulation of mutations– Choice always based on cross-resistance data

Perspectives beyond the guidelines

• Early treatment intervention to prevent disease progression ?è screening programè non invasive evaluation of liver disease / biomarkers

• Can we prevent prevent HCC development ? èdecreased risk of HCC if HBsg clearance <50 yrs (Yuen et al, Gastroenterology 2008)

• Can we clear cccDNA and/or HBsAg ?è new treatment strategiesè new treatment targets

HBsAg clearance

Werle-Lapostolle B et al., Gastroenterology 2004;126: 1750-58.

Infected hepatocytes

Infected liver

cccDNA

Antivirals

Clearance of HBsAg?

Blood circulationviral load

Lamivudine 100 mg/day

Clinical example of HBsAg clearance

HBs AgPositivity cut off: 0.05

Viral loadDetection treshold

Viral loadLog Copies/ml

HBs Ag IU/ml

*: Anti-HBs antibodyNegativation of HBe Ag May 1987HBe Seroconversion between June 87 and November 1996?

Borgniet O et al., J Med Virol , 2009;81:1336-42.

Cumulative Probability of HBsAg Loss During TDF Administration

• TDF-TDF• ADV-TDF

Switch to Open Label TDF

Cumulative probability of seroconversion to anti-HBs: 7.7% TDF-TDF 7.3% ADV-TDF

*Kaplan-Meier Heathcote E-J, et al., AASLD 2010; Poster #477.

• TDF-TDF• ADV-TDF

0 12 24 36 48 64 80 96 108 120 132 144 156 168 180 192Weeks

Percentage of TDF-TDF Patients with HBsAg Loss

Key Characteristic HBsAg Clearance by Year 4 n/N (%)

Genotype A or D 14/95 (15%)

HBV DNA ≥ 9 log10 copies/mL 12/75 (16%)

HBsAg ≥ 4.5 log10 IU/mL 14/90 (16%)

Knodell Necroinflammatory Score ≥ 9 13/114 (11%)

Heathcote E-J, et al., AASLD 2010; Poster #477.

No HBsAg loss in : Asian patients HBeAg negative patients Genotype B or C

High rate of HBsAg clearance among sustained responders to PEG-IFNα-2a ± LAM

Marcellin et al. APASL 2009* Modified ITT analysis (missing = non response); § last observation carried forward

5 years post-treatment with PEG-IFNα-2a ± LAM (N=230)

<10,000 cp/mL* <400 cp/mL* Cleared HBsAg§

Perspectives of anti-HBV immune therapy

New targets

Immune system

Conclusions 1• Maladie fréquente et grave

– 300 000 porteurs chroniques en france– 1ère cause de cancer du foie dans le monde– 1300 décès par an en France

• Maladie méconnue– Souvent asymptomatique, ou symptomes non spécifiques– Seulement 60 000 personnes connaissent leur maladie– 15 000 sont traitées

• Persistance virale– Pas d’éradication du génome viral– Surveillance prolongée, possibilité de réactivations

Conclusions 2

• Différentes formes d’hépatites en fonction de l’interaction virus / réponse immunitaire– Portage asymptomatique / hépatite chronique / cirrhose /

cancer du foie• Impact de la variabilité du génome viral

- Role dans la persistance virale et la résistance aux antiviraux- Echappement diagnostique

• Nécessité d’un dépistage et traitement précoce des formes chroniques

• Prévention par la vaccination !!!

Zoulim du 2012

Health & Medicine

yB RÈGLEMENT (UE) N o 1215/2012 DU … - Règlement 1215-2012.pdf · RÈGLEMENT (UE) N o 1215/2012 DU PARLEMENT EUROPÉEN ET DU CONSEIL du 12 décembre 2012 concernant la compétence

LA RECTOCOLITE HEMORAGIQUE Professeur Fabien ZOULIM HOTEL DIEU LYON

Zoulim du 2015

Directive 2012/34/UE du Parlement européen et du … · DIRECTIVES DIRECTIVE 2012/34/UE DU PARLEMENT EUROPÉEN ET DU CONSEIL du 21 novembre 2012 établissant un espace ferroviaire

PROCES-VERBAL DE LA SEANCE DU CONSEIL COMMUNAL DU 29 MAI 2012 · 2012-08-08 · 2 Conseil communal 2012/03 (s.p.) – Séance du 29 mai 2012 Conseil communal du 29 mai 2012 à 20

2012-03 DU

Direction Générale du Travail Décret n°2012-639 du 4 mai 2012

Odre du jour du Conseil Municipal du 9 Février 2012

Evaluation du colloque du GNDS 2012 Du 10 juin au 15 juin 2012 à Porquerolles

Plaquette Du Festival Du Jazz 2012

ULCERE GASTRODUODENAL Professeur Fabien ZOULIM HOTEL DIEU

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France

Gault du 2012

INTERNE ET EXTERNE CVS du 28 Février 2012 CVS du 28 Février 2012

Du Prefeito 2012

Zoulim vhb du16

Serfaty du 2012

Résumé du rapport d’activité du registre Eurocord 2012 · Résumé du rapport d’activité du registre Eurocord 2012 A la fin de l’année 2012, les données concernant 12

Version du 29 février 2012 - ceacap diaporama...La RT 2012 Présentation Version du 29 février 2012 Ministère de l'Écologie, du Développement durable, des Transports et du Logement

Rapport du froupe d'Experts du SMIC - 2012